Cetuximab Plus Mfolfox-6 As First-Line Therapy for Unresectable Liver Metastasis from Colorectal Cancer: An Open, Non-Randomized, Multicenter Phase II Clinical Trial

Cetuximab Plus Mfolfox-6 As First-Line Therapy for Patients with Kras Wild-Type Unresectable Colorectal Liver-Limited Metastases: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial (Clime Study)

Annals of Oncology ◽

10.1093/annonc/mdu333.100 ◽

2014 ◽

Vol 25 ◽

pp. iv204 ◽

Cited By ~ 2

Author(s):

S. Cai ◽

W. Zhang ◽

W. Li ◽

Y. Xu ◽

W. Gu ◽

...

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Phase Ii Clinical Trial ◽

Wild Type ◽

First Line ◽

First Line Therapy ◽

Multicenter Phase ◽

Capecitabine in combination with oxaliplatin as first line therapy for patients (pts) with advanced or metastatic colorectal cancer (ACRC): preliminary results of an international multicenter phase II study

European Journal of Cancer ◽

10.1016/s0959-8049(01)81497-0 ◽

2001 ◽

Vol 37 ◽

pp. S272 ◽

Cited By ~ 5

Author(s):

C. Twelves ◽

C. Butts ◽

J. Cassidy ◽

Th. Conroy ◽

F. DeBraud ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

Preliminary Results ◽

First Line Therapy ◽

Multicenter Phase ◽

Line Therapy ◽

International Multicenter

A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002)

European Journal of Cancer ◽

10.1016/j.ejca.2019.01.007 ◽

2019 ◽

Vol 109 ◽

pp. 183-191 ◽

Cited By ~ 2

Author(s):

Zhen Wang ◽

Cheng Huang ◽

Jin-Ji Yang ◽

Yong Song ◽

Ying Cheng ◽

...

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Squamous Cell ◽

Lung Carcinoma ◽

Phase Ii Clinical Trial ◽

Squamous Cell Lung Carcinoma ◽

First Line ◽

Cell Lung Carcinoma ◽

First Line Therapy ◽

Randomized, single-centered, phase II clinical trial of nimotuzumab plus cisplatin and S-1 as first-line therapy in patients with advanced gastric cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.e21021 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e21021-e21021 ◽

Cited By ~ 1

Author(s):

Y. Chi ◽

Z. Zheng ◽

A. Zhou ◽

L. Yang ◽

T. Qu ◽

...

Keyword(s):

Gastric Cancer ◽

Clinical Trial ◽

Advanced Gastric Cancer ◽

Phase Ii ◽

Phase Ii Clinical Trial ◽

First Line ◽

First Line Therapy ◽

A Four-Arm, Randomized, Multicenter Phase II Trial of Oxaliplatin Combined with Varying Schedules of 5-Fluorouracil as First-line Therapy in Previously Untreated Advanced Colorectal Cancer

Clinical Colorectal Cancer ◽

10.3816/ccc.2008.n.018 ◽

2008 ◽

Vol 7 (2) ◽

pp. 134-139 ◽

Cited By ~ 4

Author(s):

Ramesh K. Ramanathan ◽

Georg A. Bjarnason ◽

Stephen Alan Bernard ◽

Philip Desimone ◽

Theodore Braich ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Advanced Colorectal Cancer ◽

Phase Ii Trial ◽

First Line ◽

First Line Therapy ◽

Multicenter Phase ◽

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

BMC Cancer ◽

10.1186/s12885-015-1685-z ◽

2015 ◽

Vol 15 (1) ◽

Cited By ~ 12

Author(s):

Hitoshi Soda ◽

Hiromichi Maeda ◽

Junichi Hasegawa ◽

Takao Takahashi ◽

Shoichi Hazama ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

First Line ◽

First Line Therapy ◽

Multicenter Phase ◽

6098 POSTER CRAFT Trial-Result From Multicenter Phase II Study of Modified FOLFOX7 (Combination Chemotherapy of Infusional 5-FU/l-Leucovorin and Intermittent Oxaliplatin) With Bevacizumab in the First-line Therapy of Colorectal Cancer

European Journal of Cancer ◽

10.1016/s0959-8049(11)71743-9 ◽

2011 ◽

Vol 47 ◽

pp. S421

Author(s):

K. Ishibashi ◽

K. Koda ◽

M. Oshiro ◽

H. Matsuoka ◽

H. Baba ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Combination Chemotherapy ◽

Phase Ii Study ◽

Trial Result ◽

First Line ◽

First Line Therapy ◽

Multicenter Phase ◽

Multicenter phase II clinical study of the efficiency and safety of capecitabine plus intermittent oxaliplatin with bevacizumab as first-line therapy in patients with metastatic colorectal cancer (VOICE trial)

International Journal of Colorectal Disease ◽

10.1007/s00384-021-03995-7 ◽

2021 ◽

Author(s):

Chihiro Kosugi ◽

Keiji Koda ◽

Tadamichi Denda ◽

Keiichiro Ishibashi ◽

Hideyuki Ishida ◽

...

Keyword(s):

Colorectal Cancer ◽

Clinical Study ◽

Phase Ii ◽

First Line ◽

First Line Therapy ◽

Multicenter Phase ◽

Line Therapy ◽

Phase Ii Clinical Study

Voice Trial-Results from a Multicenter Phase Ii Study of Assessment of Clinical Efficacy and Safety in Capecitabine Plus Intermittent Oxaliplatin Together with Bevacizumab As the First-Line Therapy for the Patients with Advanced Colorectal Cancer

Annals of Oncology ◽

10.1093/annonc/mdu333.27 ◽

2014 ◽

Vol 25 ◽

pp. iv178

Author(s):

C. Kosugi ◽

K. Koda ◽

T. Denda ◽

K. Ishibashi ◽

H. Ishida ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Clinical Efficacy ◽

Advanced Colorectal Cancer ◽

Phase Ii Study ◽

Efficacy And Safety ◽

First Line ◽

First Line Therapy ◽

Multicenter Phase ◽

Preliminary results of an open label, uncontrolled, multicenter, phase II study evaluating the efficacy and safety of xelox plus cetuximab as first-line therapy in patients with metastatic colorectal cancer

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.15010 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 15010-15010 ◽

Cited By ~ 1

Author(s):

S. A. Barroso ◽

E. Sanches ◽

J. M. Ferreira ◽

M. Passos ◽

A. Sá ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Multicenter Phase ◽